Evidence map›Paper›PMID 39318036›Full record

ArticleGenetic epidemiology2025

PSAP-Genomic-Regions: A Method Leveraging Population Data to Prioritize Coding and Non-Coding Variants in Whole Genome Sequencing for Rare Disease Diagnosis.

Marie-Sophie C Ogloblinsky, Ozvan Bocher, Chaker Aloui, Anne-Louise Leutenegger, Ozan Ozisik, Anaïs Baudot, Elisabeth Tournier-Lasserve, Helen Castillo-Madeen, Daniel Lewinsohn, Donald F Conrad and 2 more

Abstract read
In one paragraph

Article in Genetic epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Benchmark of computational methods to detect digenism in sequencing data.European journal of human genetics : EJHG · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marie-Sophie C OgloblinskyUniv Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.ORCID http://orcid.org/0000-0002-0147-5468
Ozvan BocherUniv Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.ORCID http://orcid.org/0000-0002-2467-9236
Chaker AlouiInserm, NeuroDiderot, Unité Mixte de Recherche, Université Paris Cité, Paris, France.
Anne-Louise LeuteneggerInserm, NeuroDiderot, Unité Mixte de Recherche, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-1302-4357
Ozan OzisikINSERM, Marseille Medical Genetics (MMG), Aix Marseille University, Marseille, France.
Anaïs BaudotINSERM, Marseille Medical Genetics (MMG), Aix Marseille University, Marseille, France.
Elisabeth Tournier-LasserveInserm, NeuroDiderot, Unité Mixte de Recherche, Université Paris Cité, Paris, France.
Helen Castillo-MadeenDivision of Genetics, Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, USA.
Daniel LewinsohnDivision of Genetics, Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, USA.
Donald F ConradDivision of Genetics, Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, USA.
Emmanuelle GéninUniv Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.ORCID http://orcid.org/0000-0003-4117-2813
Gaëlle MarenneUniv Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.ORCID http://orcid.org/0000-0002-4363-7170

Funding

Project IIIP50HD096723 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Kyle Edwin Orwig · 2019 to 2026
$15.0M
GENOMICS OF SPERMATOGENIC IMPAIRMENTR01HD078641 · NICHD · WASHINGTON UNIVERSITY · PI Kenneth Ivan Aston, DONALD F. CONRAD · 2014 to 2026
$6.3M
NICHD NIH HHS L50 HD070397NICHD NIH HHS P50 HD096723NICHD NIH HHS R01 HD078641This study was jointly supported by the French Priority Research Program on Rare Diseases "Programme Prioritaire de Recherche Maladies Rares du Programme français d'Investissements d'Avenir" and by the Britanny region through the ARED program to E. Génin, and by the National Institutes of Health of the United States of America grants R01HD078641 and P50HD096723 to D. F. Conrad. This study was also supported by the INSERM GOLD Cross-Cutting program.
6 · The paper itself

Abstract

The introduction of Next-Generation Sequencing technologies in the clinics has improved rare disease diagnosis. Nonetheless, for very heterogeneous or very rare diseases, more than half of cases still lack molecular diagnosis. Novel strategies are needed to prioritize variants within a single individual. The Population Sampling Probability (PSAP) method was developed to meet this aim but only for coding variants in exome data. Here, we propose an extension of the PSAP method to the non-coding genome called PSAP-genomic-regions. In this extension, instead of considering genes as testing units (PSAP-genes strategy), we use genomic regions defined over the whole genome that pinpoint potential functional constraints. We conceived an evaluation protocol for our method using artificially generated disease exomes and genomes, by inserting coding and non-coding pathogenic ClinVar variants in large data sets of exomes and genomes from the general population. PSAP-genomic-regions significantly improves the ranking of these variants compared to using a pathogenicity score alone. Using PSAP-genomic-regions, more than 50% of non-coding ClinVar variants were among the top 10 variants of the genome. On real sequencing data from six patients with Cerebral Small Vessel Disease and nine patients with male infertility, all causal variants were ranked in the top 100 variants with PSAP-genomic-regions. By revisiting the testing units used in the PSAP method to include non-coding variants, we have developed PSAP-genomic-regions, an efficient whole-genome prioritization tool which offers promising results for the diagnosis of unresolved rare diseases.

Indexed as

Rare DiseasesWhole Genome SequencingExomeGenetics, PopulationGenetic VariationGenome, HumanGenomicsHigh-Throughput Nucleotide SequencingHumansnon‐coding variantsrare diseasesvariant prioritizationwhole‐genome sequencing

Identifiers

PMID39318036
PMCPMC12188999

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.